HPLC-verified Tirzepatide for laboratory research, dispatched domestically from Sydney & Melbourne with a Certificate of Analysis on every tested batch.
Domestic sourcing of Tirzepatide from an Australian-registered supplier avoids the customs risk, delivery delays and currency uncertainty of ordering internationally. Dispatch from Sydney and Melbourne means tracked domestic delivery without border clearance, AUD pricing, and the protections of Australian consumer law. For metabolic research programmes requiring consistent, repeatable supply, those factors are as important as the compound specification.
Tirzepatide (LY3298176) is a synthetic dual GIP/GLP-1 receptor agonist — the most advanced dual-incretin research peptide currently in the literature. It simultaneously activates the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, producing a broader pharmacological profile than GLP-1-only compounds. For a full research profile see our Tirzepatide research guide, or for a comparison with the triple-agonist class see Retatrutide vs Tirzepatide.
Tirzepatide is a larger peptide molecule than most research compounds, making rigorous purity characterisation particularly important. Every batch Pepreta supplies is characterised by RP-HPLC to ≥99% purity, ESI-MS identity confirmation and LAL endotoxin screening. The Certificate of Analysis is published per batch on the product page.
Tirzepatide and Retatrutide are both incretin-based research peptides but represent different receptor profiles. Tirzepatide activates GIP and GLP-1 receptors; Retatrutide adds glucagon receptor activity as a triple agonist. Researchers comparing dual and triple receptor pharmacology often source both for side-by-side experimental designs.
See current pricing and batch documentation on the Tirzepatide product page. Add bacteriostatic water for reconstitution at checkout. Our supplier verification guide covers what to look for when buying any research peptide.
An investigational triple GIP/GLP-1/glucagon receptor agonist for metabolic research.
Tirzepatide is supplied for in-vitro laboratory research only, not for human or animal use. Australian regulations on research chemicals vary, and it is the buyer's responsibility to ensure compliance with local law. We supply for legitimate research purposes only.
Each batch is analysed by reversed-phase HPLC to a specification of ≥99.0% purity, with mass-spectrometry identity confirmation and LAL endotoxin screening. The Certificate of Analysis is available on the product page for each tested batch.
Australian orders are dispatched within 24 hours from Sydney & Melbourne, typically arriving in 2–5 business days with tracking. Standard shipping is $9.95 (free over $149); Express is $14.95 (free over $199).
Tirzepatide is available from 10mg to 60mg per vial, as a single vial or a 10-vial pack at a 5% per-vial discount. See the product page for the full size range and current pricing.
HPLC-verified Retatrutide with a Certificate of Analysis on every tested batch. Secure checkout in AUD.
View Retatrutide →